Holen Sie sich die Stockscreener-App
6.20
58.57%
2.29
Vorhandelsmarkt:
5.95
-0.25
-4.03%
Schlusskurs vom Vortag:
$3.91
Offen:
$6.03
24-Stunden-Volumen:
21.72M
Relative Volume:
55.96
Marktkapitalisierung:
$80.22M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-102.09M
KGV:
-5.9048
EPS:
-1.05
Netto-Cashflow:
$-108.72M
1W Leistung:
+24.25%
1M Leistung:
+47.62%
6M Leistung:
+78.19%
1J Leistung:
-17.23%
1-Tages-Spanne:
$5.30
$6.7799
1-Wochen-Bereich:
$3.91
$6.7799
52-Wochen-Spanne:
$2.2045
$8.318
Dbv Technologies Adr Stock (DBVT) Company Profile
Firmenname
Dbv Technologies Adr
Sektor
Branche
Telefon
33(0)155427878
Adresse
107 AVENUE DE LA REPUBLIQUE, CHATILLON
Vergleichen Sie DBVT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DBVT
Dbv Technologies Adr
|
6.20 | 80.22M | 0 | -102.09M | -108.72M | -1.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Dbv Technologies Adr Stock (DBVT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-01-04 | Hochstufung | Societe Generale | Hold → Buy |
| 2022-12-16 | Herabstufung | Goldman | Neutral → Sell |
| 2022-05-10 | Herabstufung | Goldman | Buy → Neutral |
| 2021-09-14 | Hochstufung | Societe Generale | Hold → Buy |
| 2021-01-22 | Herabstufung | Societe Generale | Hold → Sell |
| 2020-11-02 | Hochstufung | Societe Generale | Sell → Hold |
| 2020-08-06 | Herabstufung | Societe Generale | Buy → Sell |
| 2020-08-05 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-17 | Herabstufung | Stifel | Buy → Hold |
| 2020-01-09 | Hochstufung | Stifel | Hold → Buy |
| 2019-12-16 | Eingeleitet | Citigroup | Buy |
| 2019-09-05 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-06-17 | Eingeleitet | Goldman | Buy |
| 2018-12-20 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2018-12-20 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2018-12-20 | Herabstufung | Jefferies | Buy → Hold |
| 2018-12-20 | Herabstufung | Stifel | Buy → Hold |
| 2017-10-31 | Hochstufung | Societe Generale | Sell → Hold |
| 2017-10-24 | Herabstufung | Societe Generale | Buy → Sell |
| 2017-10-23 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2017-06-23 | Eingeleitet | Deutsche Bank | Buy |
| 2017-03-16 | Hochstufung | Societe Generale | Hold → Buy |
| 2016-09-26 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2015-12-03 | Eingeleitet | Barclays | Overweight |
| 2015-10-23 | Eingeleitet | BofA/Merrill | Buy |
Alle ansehen
Dbv Technologies Adr Aktie (DBVT) Neueste Nachrichten
DBV Technologies (NASDAQ:DBVT) Coverage Initiated by Analysts at StockNews.com - Defense World
European ADRs See Mixed Results With Biopharma Leading Gains - Finimize
Why DBV Technologies (DBVT) Stock Is Skyrocketing - Benzinga
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading - TradingView
US Stocks Likely To Open Lower, Analysts Warn 'Prolonged Uncertainty Could Hurt Both US And Global Risk Assets' - Benzinga
DBV Technologies announces up to $307M financing to advance Viaskin Peanut program - MSN
DBV Technologies Announces Financing of up to $306.9 - GlobeNewswire
Major Breakthrough: $306.9M Funding Powers Revolutionary Peanut Allergy Patch to FDA Finish Line - StockTitan
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading - TradingView
DBV Technologies (NASDAQ:DBVT) vs. Jasper Therapeutics (NASDAQ:JSPR) Head to Head Comparison - Defense World
European Equities Traded in the US as American Depositary Receipts Higher in Monday Trading - TradingView
DBV Technologies faces cash shortage, stock drops By Investing.com - Investing.com South Africa
DBV Technologies faces cash shortage, stock drops - Investing.com
DBV Technologies Secures Agreement with FDA on Safety - GlobeNewswire
Major FDA Breakthrough: DBV's Peanut Allergy Treatment Path Accelerates Despite Cash Concerns - StockTitan
DBV Technologies (NASDAQ:DBVT) Coverage Initiated at StockNews.com - Defense World
European Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Track Higher in Monday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Down for Week - TradingView
DBV Technologies’ SWOT analysis: peanut allergy patch stock faces crucial trials By Investing.com - Investing.com South Africa
DBV Technologies’ SWOT analysis: peanut allergy patch stock faces crucial trials - Investing.com
European Equities Traded in the US as American Depositary Receipts Fall in Monday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Lower Wednesday - TradingView
European Equities Traded in the US as ADRs Fall in Tuesday Trading - TradingView
JMP reiterates DBV Technologies stock with $10 target - Investing.com
European Equities Traded in the US as American Depositary Receipts Surge Higher in Monday Trading - TradingView
DBV Technologies (DBVT) Projected to Post Quarterly Earnings on Thursday - MarketBeat
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Remain Flat for Week - TradingView
DBV Technologies (DBVT) to Release Earnings on Thursday - Defense World
DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress - The Manila Times
DBV Technologies (NASDAQ:DBVT) Earns Hold Rating from Analysts at StockNews.com - Defense World
Can This Peanut Patch Help Children Safely Eat 3-4 Peanuts? New 5-Year Data Reveals Promising Results - StockTitan
Bank Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher in Tuesday Trading - TradingView
DBV Technologies’ SWOT analysis: peanut allergy patch stock faces funding hurdles - Investing.com India
DBV Technologies' SWOT analysis: peanut allergy patch stock faces funding hurdles - Investing.com UK
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading - TradingView
DBV Technologies (NASDAQ:DBVT) vs. Allogene Therapeutics (NASDAQ:ALLO) Critical Contrast - Defense World
European Equities Traded in the US as American Depositary Receipts Edge Lower in Wednesday Trading - MSN
DBV Technologies (NASDAQ:DBVT) Now Covered by StockNews.com - MarketBeat
DBV Technologies (NASDAQ:DBVT) Stock Crosses Above 50-Day Moving AverageTime to Sell? - MarketBeat
European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading - TradingView
DBV Technologies stock holds firm with $10 target from JMP By Investing.com - Investing.com South Africa
DBV Technologies stock holds firm with $10 target from JMP - Investing.com India
DBV Technologies (NASDAQ:DBVT) Shares Cross Above Fifty Day Moving Average – Time to Sell? - Defense World
Finanzdaten der Dbv Technologies Adr-Aktie (DBVT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.91%
0.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):